Abstract

Growth factor stimulation induces c-Jun-dependent survival of primary endothelial cells. However, the mechanism of c-Jun anti-apoptotic activity has not been identified. We here demonstrate that in response to growth factor treatment, primary human endothelial cells as well as mouse fibroblasts respond with an increased expression of c-Jun that forms a complex with ATF2. This complex activates the expression of the anti-apoptotic protein Bcl-X(L). By site-directed mutagenesis experiments, we identified two AP-1-binding sites located within the proximal promoter of the Bcl-X gene. Site-directed mutagenesis demonstrated that these AP-1 sites are required for the transcriptional activation of the promoter. Chromatin immunoprecipitation experiments show that in response to growth factor treatment, the heterodimer c-Jun.ATF2 binds to these functional AP-1 sites. Silencing of either c-Jun or ATF2 demonstrated that both nuclear factors are required for the activation of the proximal Bcl-X promoter. Taken together, our experiments provide evidence that growth factor-independent signaling pathways converge in the formation of an active c-Jun.AFT2 dimer, which induces the expression of the anti-apoptotic factor Bcl-X(L) that mediates a pro-survival response.

Highlights

  • Whereas Jun1⁄7ATF dimers prefer to bind to the c-AMP-responsive element whose consensus is TGAGCTCA [2]

  • In response to serum or growth factors, c-Jun mRNA is induced as an early gene, and the protein is phosphorylated at serine residues 63 and 73 and at threonine 91 and 93 of its N-terminal domain by the Jun N-terminal kinase (JNK)

  • We demonstrated the presence of two functional AP-1-binding sites in both the murine and human Bcl-X genes, which are recognized by the heterodimer c-Jun1⁄7ATF2, and silencing experiments demonstrated that c-Jun and ATF2 are required for both the expression of Bcl-XL as well as protection from apoptosis, demonstrating that Bcl-XL is a critical factor regulated by c-Jun1⁄7ATF2 required for cell survival

Read more

Summary

EXPERIMENTAL PROCEDURES

Plasmid DNA Constructs—The full-length cDNA of human Bcl-XL was amplified with the oligonucleotides 5Ј-GCCACCATGTCTCAGAGCAACCGGGAG-3Ј (forward) and 5Ј-ATTTCCGACTGAAGAGTGAG-3Ј (reverse) from a human muscle cDNA library. Silencing of mouse c-Jun was performed by annealing and cloning the oligonucleotides 5Ј-TCGAGAACGCAGCAGTTGCAAACGTTTAACTTGAGAAAACGTTTGCAACTGCTGCTTTTTCTGCA-3Ј (sense) and 5Ј-GAAAAAGCAGCAGTTGCAAACGTTTTCTCAAGTTAAACGTTTGCAACTGCTGC-3Ј (antisense) into the ClaI-SalI sites of the cassette for the expression of shRNA under the U6 promoter in a lentiviral vector as previously described [9]. Human Bcl-X proximal promoter was amplified from genomic DNA with the oligonucleotides L586 (5Ј-ACCAACTAAATCCATACCA-3Ј) and L753 (5Ј-TTTTATAATAGGGATGGGC-3Ј) cloned in the in TOPO௡ PCR cloning vector and subcloned in the luciferase reporter plasmid pGL3 (Promega, Madison, WI) to obtain the pGL3-hP1wt construct. Mouse fibroblasts were grown in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum and 50 units/ml penicillin-streptomycin. For the amplification of immunoprecipitated DNA, we used the following oligonucleotides: M179 (5Ј-AAGCTTCGCAATTCCTCTGT-3Ј) and M180 (5Ј-GCCTTTCTCCAAAAGTCACC-3Ј) for the mouse Bcl-X promoter region; M554 (5Ј-CAATTCCTGTGTCGCCTT-3Ј) and M555 (5Ј-GAAAAGGCTGGTGGGAGATTCAG-3Ј) for the human Bcl-X promoter region; M550 (5Ј-TACTTCGTCTGTCTCCCTCACT-3Ј) and M551 (5Ј-AGCACCCGTTCCTTCCCTTAT-3Ј) for the human Snai promoter region; N268 (5Ј-TTGGGCCAACTTCCCAAGCA-3Ј) and N270 (5Ј-AGAGAAGGCCTTTCCACAGGT-3Ј) for the mouse Snai promoter region; and M537 (5Ј-CTAGCAAAATAGGCTGTCCC-3Ј) and M273 (5Ј-ATCACAGGTCGGGAGAGG-3Ј) for transfected plasmid DNA

RESULTS
Findings
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call